Verogen Partners with QIAGEN to Deliver Innovative Solutions for Human Identification Laboratories
June 29 2021 - 4:07PM
Business Wire
The collaboration will empower human identification laboratories
with superior tools and support needed to deliver more impactful
outcomes.
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) and
Verogen Inc. today announced a partnership to provide laboratories
with superior tools and comprehensive support for implementing
next-generation sequencing (NGS) human identification
workflows.
The partnership with QIAGEN is a milestone-driven distribution
and development agreement that grants QIAGEN rights to globally
distribute both current and future Verogen products. Verogen and
QIAGEN will also collaborate to commercialize Verogen’s
forensically validated NGS workflows with QIAGEN’s sample prep
automation to provide full sample to ID solutions for human
identification laboratories.
“Our mission is to empower the human identification community
with innovative tools that can deliver an identification, not just
a DNA profile,” said Brett Williams, Chief Executive Officer at
Verogen. “This partnership with QIAGEN will make it easier for the
laboratories to provide more impactful answers. By combining
Verogen’s industry-leading NGS-based product portfolio with
QIAGEN’s gold-standard extraction, assay, and automation solutions,
we can accelerate adoption and utilization of NGS in forensic
operations”. “This combination brings together Verogen’s innovative
NGS workflows with QIAGEN’s leading portfolio of Sample to Insight
solutions, creating the most comprehensive product offering for
forensics applications,” said Thierry Bernard, Chief Executive
Officer at QIAGEN. “The partnership will drive the adoption of NGS
in human identification as it will enable our customers to gain
even better insights from their casework samples. This will
ultimately strengthen justice systems all over the world.”
Verogen’s turnkey solutions for human identification
laboratories combine industry-leading NGS sequencing
instrumentation, proprietary library prep reagents, and sequencing
consumables with sophisticated application-specific software.
Through this partnership, QIAGEN will optimize its market-leading
sample extraction and library prep automation capabilities for the
Verogen ForenSeq® library prep kits, thereby enhancing both
companies’ channel reach and presence to support the forensic
market.
About Verogen
Verogen is a dedicated developer of DNA-based biometric human
identification products for analysis of forensic genomic samples.
Working closely with the forensic community, Verogen places
exceptional value on flexible, scalable solutions that deliver
reliable results. To learn more, visit www.verogen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. QIAGEN provides solutions
to more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). Further
information can be found at http://www.qiagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210629006036/en/
Verogen Kim Mohr Insight Communications 949-322-3733
insight.kmohr@gmail.com
QIAGEN Investor Relations John Gilardi +49 2103 29
11711
Phoebe Loh +49 2103 29 11457 ir@QIAGEN.com
Public Relations Thomas Theuringer
+49 2103 29 11826
Robert Reitze +49 2103 29 11676 pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024